Nicole, Thanks, us thank joining for all and today. you
have like revenues of begin shared on updates Starting seen, in focus this of exciting key million very to I'd to for performance. in XXXX. with, represents X% morning. a over return earlier we with quarter will you $XX.X But to the ZYNLONTA As business the some commercial news sequential our continued fourth its QX. This have growth increase quarter. items
despite in we growth continued centers intensified competitive and academic Importantly, saw landscape. both in the the community
to next pipeline. Turning our
announced dosing significant have progress. study in low month, levels successfully no We ICANS cleared bispecifics, ZYNLONTA, Last combination cohort the we CRS. of made of no no with final dose-limiting grade toxicities, arms that in and either both our or LOTIS-X with
in dose and initial plus now we expanding line We of University to kilogram are encouraging per recently the XXX time, are ZYNLONTA at DLBCL. Today, plus micrograms Miami's arm the share, glofitamab combination the from marginal response trial the the in X achieved on time at and data complete results a patients, lymphoma. partial response of II a investigator-initiated relapsed/refractory of with XX first Based Phase initial ZYNLONTA maintaining patients response XXX from first second for presented data evaluable cutoff. all zone delighted in XX achieved
the dose the enroll pancreatic are sarcoma in novel patients, process to optimizing We of and enrolling schedule. and began we our continue cancer ADC. Moving and patients ADCT-XXX, targeting AXL to
our early for first comprehensive shared solid ADC update Lastly, time data at platform, tumor the candidates investor on preclinical exatecan-based X event. our recent preclinical we novel our a on research including
we our expenses strategy basis. in decreased a XX% ended This, cash turn, manage of us maintained quarter we operating disciplined the Finally, and million. burn, allocation our first non-GAAP enabled in in that so $XXX.X year-over-year to terms of our by corporate with QX update, capital on cash
raise just in to of an Friday have this, we announced at included warrants have to is offering and underwritten top priced on share price prefunded and we common gross that million shares close the May proceeds. expected on closing $XXX X. today per On The offering
We runway mid-XXXX, with flexibility will this company execute enhanced provide and expect the extend financial cash our to strategy. our into
our value everyone we the would strategy I we strength company. pursuing, Given remind see unlock the are which and in to tremendous will balance like sheet, believe of the we
a the Within prioritized hematology. company remains our asset profitability. product focus primary expect the to and which to pillar have through carry ZYNLONTA, in derisked this, first in Our we portfolio, key we
the our capital deploying lines to pursue to are earlier potential the in of opportunity such DLBCL franchise ZYNLONTA plus the indolent DLBCL and on our larger indication and to majority We lymphomas, therapy marginals commercialize lymphoma. as of third-line existing substantially
We and peak opportunities annual in generate the believe these help will potential sales the ZYNLONTA of expand to franchise potential $X.X billion. have excess
Behind solid asset. targets The advanced we the tumor of pipeline. ADCT-XXX to our our interest second ADCs pillar most tumor emerging of broad by is driven solid exatecan-based potential advance novel our against a grounded of is strategy see this, our portfolio in differentiated platform.
LOTIS-X expand substantially into to I'd indolent opportunity in and therapy for the DLBCL now lines ZYNLONTA earlier expand DLBCL. larger LOTIS-X goal Pending results second-line usage studies, like and the ZYNLONTA of is potential of lymphomas. of our to on plus the
with confirmatory our study ZYNLONTA Phase rituximab. LOTIS-X of is combination in reminder, a As III
our we the enrollment as we as in of If and believe with early the XXXX. remain full into track combination headline potentially plus Here, and by rituximab, the of trial second of a by expect this DLBCL readout the XXXX. for potential this to will for positive, ZYNLONTA end with on expand year, line end indication complete lead end approval to
of LOTIS-X ZYNLONTA Phase combination Ib in trial is with bispecifics. our
and well amongst the escalation. We are in initial of tolerability X majority the part the encouraged by safety anti-tumor the observed activity of as as patients profile dose
before additional to now complete enrollment are line expect with and ZYNLONTA and X second data plus in DLBCL in share enrolling We plan Part expansion safety and to year-end. dose glofitamab plus efficacy
investigator-initiated second-line Lymphoma based are the by who Lymphoma Marginal Zone lead the MZL to the Research MZL of that scientific the lymphoma we investigator, and available potential ZYNLONTA uses are lymphoma into want the University X,XXX see to trial's represents Lossos publicly from data the at on trials of XXXX an drug past Relapsed/refractory to workshop University need, treated zone weekend at Miami. Foundation's the also plus Dr. shared this the data, U.S. zone patients the data expand Today, incidence on marginal lymphoma of an second-line Izidore initial unmet at setting follicular focus We I based estimated in Miami. X,XXX marginal plus there on
remains other CR MZL, treatment. plus MZL approved sample rates second-line are and sizes of or regimens XX% the relapsed/refractory treatment than need plus are this supporting in the guidelines. in and in modest several study Complete response At approved there small. data less medical are in FDA second-line for regimens preferred Unmet present, NCCN X for preferred NCCN included relatively
data regimen X achieved are University IIT fixed II a response outcomes ZYNLONTA treatment. rates continue evaluable agent showed XX achieved to higher response partial in clinicians duration from agents patients XX Initial as of is predictor MZL, multicenter a response. to and with safety rates, the MZL novel complete The in of duration patients. and time-related leading of study treat a fixed first single and a XX profile relapsed/refractory Miami a seek Phase strong a CR As manageable durable a complete
City was According Hope, accelerate of to currently to currently X and investigator, University the the safety There enrolling, generally are to of sites was tolerated, enrollment. sites well and known Miami lead ZYNLONTA and lead consistent profile. is the investigator trial with X expanding
As pursue soon regulatory we in have it as to pathway plan assuming our compendia sufficient and remains parallel. strategy we data, positive, potentially
price opportunity in million believe addressable the based patient captured annual million NPL has peak XX% $XX of we If analysis, opportunity. on approximately the opportunity successful, of means our at total potential cycles. second-line of valued a and market expected $XXX of number terms sales incremental it plus average share represents every peak market population ZYNLONTA In
potential data current either MZL Phase MZL MZL. CDXX-based online to similar continue While ZYNLONTA of addition NCCN still could NHL or growth for opportunity an this in and offer early studies The guidelines standard strategy in modest studies overall to on below second-line into includes if expand which larger BTK inclusion contribute FDA in NHL. single-arm in regimens were and the rates, based CR used approvals The to are to a yield results, the IIT, trial indolent care in the inhibitors subset of II XX%.
fixed must X patients the X least at antibody, of receive will years survival protocol, cycles followed survival XX included The rate or weeks. XX under protocol, measured at patients treatment and up X XX systemic as overall CR therapy, patients duration to lines endpoint with ZYNLONTA is the across more all of have failed Per study months months. including anti-CDXX of of a X for primary progression-free and at X be
predetermined efficacy set threshold XX% at CR futility rate. The was for
baseline few this is subtypes. overall want believe a patients the out. initial including the things the population, I point MZL at patients are of the characteristics so Looking there enrolled MZL far study, of representative We in to group of
so meaning the typically with treatment, XX the of patients XX group is initial MZL In they treated IV as within that the POD XX X ZYNLONTA to progressed of were with treat. XX, far, Stage patients designated of of harder addition months XX a
from ranging on X. treatment. X included X currently is see therapy can systemic right available of lines And multiple to of the prior median you side the slide, The as
Lymphoma workshop of Zone XX As additional X, shared by Dr. Losses a at May Marginal patients achieved on with Foundation's Lymphoma patient results achieving XXXX a Research these initial showed PR. XX CR scientific X the
X X CRs, after cycles. XX the Of achieved were
the addition, tolerated an longest maintain was data known generally consistent achieving this as a lead safety And from all safety perspective, initial study, profile. of per the and approximately ZYNLONTA them well reaching patients the cutoff responses In responder investigator XX months. with in and with
trial, cycle in Miami's patient from respectively. we II Based of second CR at due on relapsed/refractory fully encouraged X second in are discontinued University this plus resolved Phase line after for a Both X, the the with rare months, treatment. initial remain in XX by data MZL, cycle patients of this a discontinuation which opportunity patient and ZYNLONTA toxicity to after disease. patients these upon discontinued evaluating One potential setting X of
additional from escalation dose safety sharing LOTIS-X, we of data to here the on portion X Part the are study. Moving
are of ICU were than CRS Those Grade observed. for X that The or management pressers. managed grade that X majority experienced a have who greater is the patients X with CRS events were no requirement and important no Grade takeaways CRS
which grade of X higher glofitamab some the side, third-line plus Part On dosing the debulking study. was will the rate We XX%, and week to overall is events. focus a XX% label CRS that including glofitamab the you with the for prior Important glofitamab includes may X of current to that see ZYNLONTA believe CRS DLBCL left-hand note be that rate, with combination tumor.
hosted to tumor our based which ADC virtual comprehensive and platform research research our provided April We Turning a X event overview platform. investor research novel our exatecan X, strategy, of our solid a candidates. on lead
on candidates non-small cancers. lung is colorectal, prostate, ovarian focus against ADC and cell advancing Our endometrial differentiated cancer,
large armamentarium. remains For offers opportunities are a Furthermore, of survival part tumor each combination case, the treatment each needed. the options better indicates type, treatment chemotherapy in and of that and X-year incidents potential key
novel lead We ADC of our and offers patients cancer to exatecan care ASCTX. for based the Claudin-X, each PSMA potential each standard improve X and the platform. are utilizes Our NaPiXb, targets believe
Preclinical work index, of suggest have the our reflecting candidates ADC. therapeutic a X proprietary that the design lead each high
month. stage, data our are in are exciting ADCs IND-enabling on these we and share of early Claudin-X terms at NaPiXb pleased to last AAGR and In studies,
are the we and ADCs PSMA drug year. which complete to in selection Our expect ASCTX stage, this candidate
move IND portfolio. X to collaborations ahead, broad to research plan Looking to to advance forward and we seek a candidate with
Pepe. the Given value that, outcome market With opportunity, and or with in to early would the successful over the like potential call unmet the future. I create lives to for transform one our medical more a the significant need, has to of the research programs turn coupled patients of
